Finasteride-induced hepatitis [1];Hepatitis por finasterida

Farmacia Hospitalaria

Volumn 30, Issue 6, 2006, Pages 385-

  Martinez De Guzman M ^a   Martinez Crespo J J ^a  

^a HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FINASTERIDE; OMEPRAZOLE;

ADULT; ALOPECIA; BLOOD TRANSFUSION; CASE REPORT; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; ENZYME BLOOD LEVEL; HEPATITIS; HUMAN; LETTER; SEROLOGY;

EID: 33846845017     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)74011-9     Document Type: Letter

References (8)

1. Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc 2003; 8: 20-3.
2. Stough D, Stenn K, Haber R, Parsely WM, Vogel JE, Whiting DA, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc 2006; 81: 267.
3. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005; 4: 380-2.
4. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, et al. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92: 73-9.
5. Ficha ténica Propecia®. Laboratorio Merck Sharp and Dohme de España, S.A. Última revisión: marzo 2004.
6. Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother 2004; 5: 933-40.
7. Kaufman KD, Dawber RP. Finasteride, a type 2 5 alpha reductase inhibitor in the treatment of men with androgenetic alopecia. Expert Opin Investig Drugs 1999; 8: 403-15.
8. Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003; 13: 150-60.